TY - JOUR
T1 - Summary of phase II data of docetaxel (taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer
AU - Fossella, F. V.
AU - Jin Soo Lee, Soo Lee
AU - Berille, J.
AU - Waun Ki Hong, Ki Hong
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1995
Y1 - 1995
N2 - Six phase II studies have been conducted in the United States and Europe using docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) for advanced non-small cell lung cancer. One hundred eighty chemotherapy-naive patients in four studies and 88 patients who failed prior platinum-containing chemotherapy in two studies were treated with docetaxel 75 to 100 mg/m2 intravenously over 1 hour every 3 weeks. Fifty-nine percent of patients had adenocarcinoma and 82% had stage IV disease. At a dose of 100 mg/m2, 30% of evaluable chemotherapy-naive patients (27% of the intent-to-treat population) and 20% of evaluable platinum-refractory/resistant patients (17% of the intent-to-treat population) achieved a partial response; projected median survival is 9 months in both studies. Neutropenia was the primary dose- limiting acute side effect. Fluid retention, which occurred in patients who received multiple courses of treatment, was common but rarely dose-limiting, and may be ameliorated with prophylactic corticosteroids. Other toxic effects were relatively mild. Docetaxel has significant activity against advanced non-small cell lung cancer, producing a major response in both chemotherapy- naive patients and patients who had failed prior platinum-containing chemotherapy.
AB - Six phase II studies have been conducted in the United States and Europe using docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) for advanced non-small cell lung cancer. One hundred eighty chemotherapy-naive patients in four studies and 88 patients who failed prior platinum-containing chemotherapy in two studies were treated with docetaxel 75 to 100 mg/m2 intravenously over 1 hour every 3 weeks. Fifty-nine percent of patients had adenocarcinoma and 82% had stage IV disease. At a dose of 100 mg/m2, 30% of evaluable chemotherapy-naive patients (27% of the intent-to-treat population) and 20% of evaluable platinum-refractory/resistant patients (17% of the intent-to-treat population) achieved a partial response; projected median survival is 9 months in both studies. Neutropenia was the primary dose- limiting acute side effect. Fluid retention, which occurred in patients who received multiple courses of treatment, was common but rarely dose-limiting, and may be ameliorated with prophylactic corticosteroids. Other toxic effects were relatively mild. Docetaxel has significant activity against advanced non-small cell lung cancer, producing a major response in both chemotherapy- naive patients and patients who had failed prior platinum-containing chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0029044996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029044996&partnerID=8YFLogxK
M3 - Article
C2 - 7740327
AN - SCOPUS:0029044996
SN - 0093-7754
VL - 22
SP - 22
EP - 29
JO - Seminars in oncology
JF - Seminars in oncology
IS - SUPPL. 4
ER -